New drug cocktail hopes to tackle advanced colon cancer
NCT ID NCT07621159
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called HDM2017 combined with standard treatment (fruquintinib) in 120 people with advanced colorectal cancer that has spread. The goal is to find the safest dose and see if the combination can shrink tumors. Participants must have tried other treatments and have a life expectancy of at least 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HDM2017 combined with fruquintinib
What this could lead to
If successful, this could lead to a new treatment option for advanced colorectal cancer that may shrink tumors or slow disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 120 participants, so results may not confirm effectiveness. Side effects from the drug combination are unknown and could be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••